Cancer Cell 2017 07;32(1):6-8
University of California, San Francisco, CA, USA. Electronic address:
|PDF Download - Full Text Link
( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)
Prog Urol 2013 Oct;23 Suppl 1:S34-43
Service d'urologie, hôpital Foch, université de Versailles - Saint-Quentin-en-Yvelines (UVSQ), 92150 Suresnes, France. Electronic address:
Introduction: New drugs have recently been developed, through a better understanding of the mechanisms involved in the progression of prostate cancer, including castration-resistant ones (CRPC). This article aims to describe the mechanisms of action of these new hormonal treatments and their major clinical outcomes and development programs.
Materials And Methods: A bibliographic research in French and English using Medline(®) and Embase(®) using the keywords "castration-resistant prostate cancer", "abiraterone acetate", "orteronel", "enzalutamide", and "clinical trials" was performed. Read More
Drug Des Devel Ther 2012 16;6:13-8. Epub 2012 Jan 16.
Division of Hospital Medicine, UMass Memorial Healthcare, Worcester, MA 01605, USA.
Prostate cancer is the second leading cause of cancer death in men in the US and Europe. The treatment of advanced-stage prostate cancer has been androgen deprivation. Medical castration leads to decreased production of testosterone and dihydrotestosterone by the testes, but adrenal glands and even prostate cancer tissue continue to produce androgens, which eventually leads to continued prostate cancer growth despite castrate level of androgens. Read More
Arch Esp Urol 2018 Mar;71(3):267-275
Servicio de Urología. Hospital Universitario 12 de Octubre. Madrid. España.
Objectives: The treatment of metastatic prostate cancer has remained unchanged for more than 70 years, based on androgen deprivation therapy (ADT). In 2015, following the CHAARTED and STAMPEDE trials, it was established that the addition of 6 cycles of docetaxel to ADT was associated with significantly increased survival. In June 2017, the LATITUDE trial and the G arm of the STAMPEDE trial showed that the addition of Abiraterone with Prednisone (5 mg/day) to ADT was also associated with a significant increase in survival in metastatic patients. Read More
Bull Cancer 2014 Apr;101(4):388-93
Institut Gustave-Roussy, DITEP, Département d'innovations thérapeutiques et essais précoces, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France.
Abiraterone acetate (AA) is a selective inhibitor of cytochrom p450 (CYP)17 which is required for androgen biosynthesis, and can block the androgens synthesis by testicles, surrenals and intratumoral secretion. In phase I and II studies in patients with prostate cancer, therapy with AA 250-2000 mg once daily demonstrated reductions in prostate specific antigen (PSA), and/or circulating tumor cells (CTCs). In two large phase III trials in patients with metastatic castration resistant prostate cancer (CRPC) in post-docetaxel and pre-docetaxel setting, AA plus prednisone compared with placebo plus prednisone demonstrated a significant superior overall survival in post-docetaxel setting, and a superior radiological PFS in pre-docetaxel setting. Read More